Lactate Dehydrogenase (LDH): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Lactate dehydrogenase is a cytoplasmic enzyme found in nearly all cells of the body, with highest concentrations in heart, liver, skeletal muscle, kidney, red blood cells, and certain cancers. It catalyses the reversible conversion of lactate to pyruvate and is released into the bloodstream when cells are damaged or destroyed. Because it is so widely distributed, LDH is a sensitive but entirely non‑specific marker of tissue injury.

Despite its lack of specificity, LDH remains clinically valuable in several well‑defined contexts:

· Haemolytic anaemias – red cell destruction releases large quantities of LDH‑1 and LDH‑2

· Megaloblastic anaemias (B12/folate deficiency) – intramedullary destruction of abnormal erythroblasts causes markedly elevated LDH

· Cancer – elevated LDH correlates with tumour burden, necrosis, and poor prognosis in lymphomas, leukemias, germ cell tumours, and many solid malignancies

· Tissue infarction – myocardial infarction (historically), pulmonary embolism, renal infarction, bowel ischaemia

· Monitoring chemotherapy response – particularly in germ cell tumours and lymphomas

· Prognostic marker – in sepsis, COVID‑19, and critical illness

LDH isoenzymes (LDH‑1 through LDH‑5) provide tissue‑specific information but are seldom ordered routinely; total LDH remains the primary screening test.

---

2. What does it measure

a. Units of measurement

· Conventional: Units per litre (U/L)

· SI: Microkatal per litre (µkat/L); 1 U/L = 0.0167 µkat/L

b. Normal range

Reference intervals vary significantly by laboratory, assay method, temperature, and patient age. The following are approximate adult ranges.

Population Typical reference range (U/L)

Adults (18–65 years) 140 – 280 U/L

Older adults (>65 years) Slightly higher; up to 300–350 U/L

Children Higher than adults; declines through adolescence

Newborns Up to 600 U/L (physiological)

Critical note: Haemolysed specimens are the single most common cause of falsely elevated LDH. Always check for haemolysis indices before interpreting a high result.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise LDH)

· Haematologic:

· Haemolytic anaemias (sickle cell, hereditary spherocytosis, G6PD deficiency, autoimmune haemolysis, microangiopathic haemolytic anaemia, transfusion reactions)

· Megaloblastic anaemias (vitamin B12 or folate deficiency) – often extremely high (500–5000 U/L) due to ineffective erythropoiesis

· Leukaemias, lymphomas, myeloma

· Cardiovascular:

· Myocardial infarction (LDH rises 12–24 hours, peaks 48–72 hours, returns to baseline 7–10 days; now largely replaced by troponin)

· Pulmonary embolism, right heart strain

· Myocarditis, pericarditis

· Hepatobiliary:

· Hepatitis (viral, alcoholic, ischaemic), cirrhosis, obstructive jaundice (mild elevation)

· Renal:

· Renal infarction, acute kidney injury, pyelonephritis

· Musculoskeletal:

· Rhabdomyolysis, muscular dystrophy, polymyositis, strenuous exercise, trauma, status epilepticus

· Pulmonary:

· Pneumonia (bacterial, viral), ARDS, COVID‑19 (elevation correlates with severity)

· Gastrointestinal:

· Bowel infarction, pancreatitis, mesenteric ischaemia

· Malignancy:

· Solid tumours (especially with necrosis: lung, colon, breast, melanoma), germ cell tumours (seminoma, dysgerminoma, teratoma) – used as tumour marker

· Medications:

· Chemotherapeutic agents (tumour lysis syndrome)

· Statins (rare myopathy)

· Valproate, isoniazid, certain antiretrovirals

· Other:

· Hypothyroidism (myxoedema)

· Carbon monoxide poisoning

· Severe burns, heatstroke

b. Indirect correlation (factors influencing interpretation)

· Haemolysis – in vitro lysis of red cells releases LDH‑1; the most frequent cause of spurious elevation. Serum LDH is typically 20–40% higher than plasma LDH due to platelet release during clotting; plasma (heparin) is preferred.

· Strenuous exercise – transient elevation (24–48 hours) from muscle membrane permeability.

· Pregnancy – mild elevation possible in third trimester.

· Age – children have higher baseline; elderly may have slightly higher values.

· Sex – no consistent difference.

· Race – some studies show slightly higher LDH in African American individuals.

· Platelet count – thrombocytosis can elevate serum LDH (platelets contain LDH); plasma specimens avoid this.

· Sample storage – LDH is unstable; samples should be processed within 2–3 days at 4°C; freezing degrades activity.

· Medications – high‑dose ascorbic acid (vitamin C) can interfere with certain enzymatic assays, causing falsely low LDH.

---

4. Disorders related to abnormal values

a. When elevated (clinically significant)

Haematologic emergencies:

· Acute haemolytic anaemia: sudden rise in LDH, indirect bilirubin, reticulocytes; decreased haptoglobin.

· Megaloblastic anaemia: LDH often >1000 U/L, with macrocytosis, hypersegmented neutrophils, low B12/folate.

· Tumour lysis syndrome: massive LDH elevation following chemotherapy; metabolic emergency (hyperkalaemia, hyperuricaemia, hypocalcaemia, acute kidney injury).

Malignancy:

· Lymphoma: LDH is part of the International Prognostic Index (IPI) for non‑Hodgkin lymphoma; high LDH indicates worse prognosis.

· Leukaemia: elevated at diagnosis; correlates with white blood cell count.

· Germ cell tumours: LDH is a standard tumour marker alongside AFP and hCG; used for staging and monitoring response.

· Metastatic solid tumours: non‑specific but suggests high tumour burden and necrosis.

Ischaemia / infarction:

· Myocardial infarction: historical marker; now troponin is gold standard.

· Bowel infarction: markedly elevated LDH with abdominal pain, lactic acidosis; surgical emergency.

· Renal infarction: sudden flank pain, haematuria, elevated LDH (often >1000 U/L), normal urine sediment.

Infections and inflammation:

· COVID‑19: elevated LDH independently predicts severe disease, ARDS, and mortality.

· Pneumonia: correlates with extent of parenchymal involvement.

· Sepsis: non‑specific but prognostic.

Muscle injury:

· Rhabdomyolysis: LDH elevated with CK, myoglobin; often >1000 U/L.

· Statin‑induced myopathy: dose‑dependent; usually resolves with drug cessation.

Extreme elevations (>1000 U/L):

· Strongly suggests:

· Megaloblastic anaemia

· Haemolytic anaemia (sickle cell crisis, G6PD deficiency, autoimmune)

· Tumour lysis syndrome

· Extensive metastatic cancer

· Shock liver (ischaemic hepatitis)

· Bowel or renal infarction

b. When low

· Rare and usually not clinically significant.

· Reported with high‑dose vitamin C supplementation (interference with certain laboratory assays).

· Massive transfusion (dilutional).

· Advanced liver disease with impaired synthetic function? (uncommon; other enzymes more affected).

---

5. Best way to address aberrant levels

Critical principle: LDH is a marker of cell damage, not a condition itself. Treating the number without identifying the cause can delay diagnosis of life‑threatening illness – particularly haemolytic anaemia, occult malignancy, or surgical abdomen. All interventions must be directed at the underlying disease.

a. Quick ways or using Medications

Cause‑specific therapy – examples:

· Haemolytic anaemia:

· Autoimmune: corticosteroids (prednisolone), IVIG, rituximab, splenectomy

· Sickle cell crisis: hydration, oxygen, analgesia, transfusion

· G6PD deficiency: remove oxidant trigger

· Hereditary spherocytosis: folate (methylfolate) supplementation, splenectomy

· Megaloblastic anaemia:

· Vitamin B12 deficiency: hydroxocobalamin or methylcobalamin intramuscular; never cyanocobalamin

· Folate deficiency: L‑methylfolate (active form), not synthetic folic acid

· Malignancy:

· Chemotherapy, radiation, targeted therapy, immunotherapy

· Tumour lysis syndrome: aggressive hydration, rasburicase, allopurinol, correction of electrolytes

· Infection:

· Antibiotics, antivirals, supportive care

· Ischaemia / infarction:

· Revascularisation (PCI, embolectomy), anticoagulation, surgical resection

· Drug‑induced myopathy:

· Discontinue offending agent (statin, fibrate); consider CoQ10 supplementation

b. Using Supplements or Holistic medicine

Supportive, adjunctive – never primary therapy for elevated LDH.

For haemolytic anaemias / high red cell turnover:

· Folate (active form): Essential in chronic haemolysis to meet increased demands of erythropoiesis.

· Must use: L‑methylfolate (calcium salt). Synthetic folic acid requires reduction by dihydrofolate reductase, a rate‑limited enzyme; unmetabolised folic acid may accumulate and is associated with adverse outcomes.

· Dietary source: Leafy greens, legumes; therapeutic doses require supplementation.

· Vitamin B12 (active form): Only if deficiency confirmed.

· Must use: Methylcobalamin or adenosylcobalamin. Never cyanocobalamin – synthetic, poorly converted, requires hepatic activation; may elevate cyanide in renal impairment.

· Source: Fermentation‑derived methylcobalamin; ecological, plant‑based.

· Iron: Only if iron deficiency coexists (uncommon in pure haemolysis).

· Preferred forms: Liposomal iron (ferric pyrophosphate citrate) or ferrous bisglycinate.

· Vitamin E: Historically used in G6PD deficiency and thalassaemia; evidence weak. Caution: high doses may worsen bleeding risk; not routinely recommended.

For statin‑induced myopathy (elevated LDH with muscle symptoms):

· Coenzyme Q10 (Ubiquinol): Statins deplete CoQ10; supplementation (200–400 mg/day) may reduce myalgia in some patients.

· Preferred form: Ubiquinol (reduced, better absorbed).

· Source: Fermentation‑derived; ecological.

For cancer‑related supportive care:

· Curcumin: Anti‑inflammatory, antioxidant; may reduce oxidative stress and LDH in some preclinical models.

· Must use bioavailable formulation: Phytosome, liposomal, nanoparticle, or with piperine. Plain curcumin is ineffective systemically.

· Caution: May interfere with certain chemotherapy agents (e.g., irinotecan). Always consult oncologist before initiating.

· Green tea extract (EGCG): Limited evidence for LDH reduction; possible hepatoprotective effects.

· Use standardised to ≥50% EGCG; avoid high doses (hepatotoxicity).

· Omega‑3 fatty acids (EPA/DHA): Anti‑inflammatory; may reduce cachexia and systemic inflammation.

· Preferred source: Algae oil – sustainably fermented, re‑esterified triglyceride form, highest bioavailability. No marine contaminants.

· Avoid: Conventional fish oil – ecological strain, bioaccumulated toxins.

· Ashwagandha (Withania somnifera): Adaptogen; may reduce fatigue and improve quality of life; no direct LDH‑lowering evidence.

Herbs and Phytochemicals from Indian subcontinent:

· Amla (Emblica officinalis): Rich in vitamin C and polyphenols; potent antioxidant. May reduce oxidative damage in haemolytic anaemias and support liver health.

· Form: Fresh fruit, powder, or standardised extract.

· Tulsi (Ocimum sanctum): Adaptogenic, hepatoprotective, anti‑inflammatory. Traditionally used in fever, respiratory disorders, and stress.

· Form: Leaf extract, tea.

· Guduchi (Tinospora cordifolia): Immunomodulatory, hepatoprotective. Used in Ayurveda for chronic fever, jaundice, and anaemia. Small studies suggest reduced liver enzymes.

· Form: Standardised aqueous extract.

· Punarnava (Boerhavia diffusa): Traditionally used for kidney and liver disorders; diuretic, anti‑inflammatory.

· Ashwagandha (Withania somnifera): May reduce muscle damage and stress; limited LDH data.

· Curcumin (Turmeric): As above.

Important cautions – supplements and LDH:

· High‑dose vitamin C can interfere with certain LDH assays, causing falsely low results. If taking >1 g/day, inform laboratory.

· Never combine antiplatelet herbs (garlic, ginkgo, high‑dose vitamin E) with anticoagulants without medical supervision.

· Avoid all proprietary blends containing synthetic folic acid, cyanocobalamin, or undeclared herbal adulterants.

· Stop all non‑essential herbs/supplements 7 days before bone marrow biopsy or major surgery.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

No diet directly lowers LDH. Dietary management targets the underlying condition and supports overall cellular health.

For haemolytic anaemias / high erythropoietic demand:

· Folate‑rich foods: Lentils, chickpeas, black‑eyed peas, asparagus, spinach, beets, okra. Steam lightly to preserve folate.

· Iron‑rich plant foods: Pumpkin seeds, sesame seeds, tofu, tempeh, lentils, amaranth leaves, moringa powder. Combine with vitamin C (lemon, amla, capsicum) to enhance absorption.

· Avoid fava beans if G6PD deficiency confirmed.

For megaloblastic anaemia (B12/folate deficiency):

· Vitamin B12 plant sources: Fortified plant milks, nutritional yeast (check for methylcobalamin), tempeh, shiitake mushrooms. Note: Strict vegetarians are at risk; supplementation is usually required for deficiency.

· Folate sources: As above.

For liver health (if LDH elevation originates from hepatitis):

· Cruciferous vegetables: Broccoli, cauliflower, kale, cabbage – support phase II detoxification.

· Beetroot: Betaine supports liver function.

· Artichoke: Cynarin; traditional hepatoprotective.

· Turmeric + black pepper: Daily culinary use.

· Avoid alcohol completely.

For cardiovascular / anti‑inflammatory support:

· Mediterranean‑style, whole‑food, plant‑dominant pattern.

· High fibre, polyphenols, unsaturated fats.

· Emphasise vegetables, fruits, legumes, whole grains, nuts, seeds, olive oil.

· Limit refined carbohydrates, ultra‑processed foods, added sugars, industrial seed oils.

Fungi:

· Shiitake, maitake, oyster, reishi: Contain beta‑glucans and ergothioneine; immunomodulatory and hepatoprotective.

· Mycoprotein (Fusarium venenatum): Sustainable meat alternative; neutral.

Algae:

· Spirulina, chlorella: Nutrient‑dense; some evidence of hepatoprotection. Caution in autoimmune disease.

Dairy and eggs:

· Permitted but not emphasised. Fermented dairy (yoghurt, kefir) preferable.

Foods to absolutely avoid:

· Alcohol – direct hepatotoxin; interferes with folate metabolism.

· Trans fats (partially hydrogenated oils) – pro‑inflammatory.

· Red and processed meat – entirely avoidable; ecological and health rationale.

· Excess refined sugar, high‑fructose corn syrup.

---

6. How soon can one expect improvement and the ideal time frame to retest

Resolution depends entirely on the underlying cause.

· Megaloblastic anaemia (B12/folate replacement):

· LDH begins to fall within 48–72 hours of adequate replacement.

· Normalisation by 1–2 weeks.

· Reticulocytosis peaks at 5–7 days.

· Retest at 2 weeks to confirm normalisation.

· Haemolytic anaemia (treated):

· Autoimmune haemolysis (steroids): LDH declines within 3–7 days.

· Sickle cell crisis: LDH normalises over 1–2 weeks with resolution of crisis.

· Retest weekly until stable.

· Tumour lysis syndrome:

· LDH rises acutely with chemotherapy, then falls over 3–7 days with effective management.

· Monitor daily during acute phase.

· Chemotherapy for lymphoma/germ cell tumours:

· LDH declines over weeks to months with response; persistent elevation suggests residual disease.

· Retest before each treatment cycle.

· Infection (pneumonia, COVID‑19):

· LDH normalises with clinical recovery; typically 1–3 weeks.

· Retest at follow‑up if clinically indicated.

· Myocardial infarction:

· LDH peaks day 3, normalises by day 7–10. Not routinely monitored.

· Statin‑induced myopathy:

· LDH normalises 2–4 weeks after drug cessation.

· Exercise‑induced elevation:

· Returns to baseline within 24–48 hours.

General retesting principles:

· Use the same laboratory and same specimen type (plasma preferred) for serial comparisons.

· Always exclude haemolysis as a preanalytical cause before acting on an elevated LDH.

· Do not retest more frequently than 48 hours for acute conditions; meaningful change requires time.

---

Conclusion

Lactate dehydrogenase is the great generalist of blood tests – ubiquitous, sensitive, and maddeningly non‑specific. An elevated LDH tells you that cells have been damaged, but not which cells, by what mechanism, or how urgently. It is the clinical equivalent of a smoke alarm: it demands investigation, not complacency.

The diagnostic possibilities span haematology (haemolysis, megaloblastic anaemia), oncology (lymphoma, germ cell tumours, metastatic disease), cardiopulmonary medicine (infarction, embolism), gastroenterology (bowel ischaemia), and critical care (sepsis, shock). Context – history, examination, other laboratory findings – is everything.

Treatment is always cause‑specific. There is no “LDH‑lowering diet” or “LDH‑normalising herb.” Adjunctive measures – active folate in chronic haemolysis, methylcobalamin in B12 deficiency, CoQ10 in statin myopathy, and ecologically responsible anti‑inflammatory nutrition – support the patient while the underlying disease is addressed. They do not replace diagnosis or definitive therapy.

As with all blood tests, interpret LDH not in isolation, but as one thread in the tapestry of the whole patient.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

Special note on B12 and folate:

Strictly plant‑based diets require reliable vitamin B12 supplementation. Choose methylcobalamin or adenosylcobalamin from fermentation sources. For folate, L‑methylfolate is the active, ecologically responsible form. Avoid synthetic folic acid and cyanocobalamin in all proprietary blends.

-x-x